Migraine disease can be challenging to treat, but it may be even more complicated for patients who have also dealt with concussions and/or PTSD. Current evidence suggests that having one of those conditions puts a patient at risk for more complicated, intractable symptoms for the other conditions.
2018 may have been a pivotal year in migraine treatment with the release of CGRP monoclonal antibodies, but that was merely the first wave of new treatments for people with migraine disease. As 2019 winds down, there are more promising treatments in the pipeline than ever before, all aiming at different targets in the migraine process. Some are new kinds of medications that may abort or prevent attacks with fewer risks than other currently available treatments. Others are neuromodulators, devices that patients can apply externally to disrupt the electrical signals during migraine attacks.